Concentrations of cefuzoname in cerebrospinal fluid (CSF) were determined in a total of 16 rabbits, 5 with healthy meninges, 5 with Staphylococcus aureus meningitis, and 6 with Escherichia coli meningitis. Mean percentages of the maximum concentration of the drug in CSF versus that in serum were 0.57, 3.37, and 4.40% for healthy rabbits, those with staphylococcal meningitis, and those with E. coli meningitis, respectively. The percentages of the area under the concentration-time curve of cefuzoname in CSF versus that in serum were, in the order of healthy group, staphylococcal meningitis group, and E. coli meningitis group, 0.61, 4.99, and 8.04% at 15 to 60 min, 1.44, 7.09, and 12.7% at 15 to 120 min, and 1.87, 8.07, and 15.8% at 15 to 180 min after administration, showing significant differences between the healthy and meningitis groups. All of the values in the E. coli meningitis group were greater than those of the staphylococcal meningitis group, but the differences were not significant. The ratios of the half-life of cefuzoname in CSF to that in serum were 2.10, 1.98, and 3.37 for the healthy, staphylococcal meningitis, and E. coli meningitis groups, respectively, with no significant difference between the three groups. Cefuzoname seems to be among the middle ranks of P-lactam agents as far as penetration rate is concerned; however, when its potent antibacterial activity and broad spectrum are taken into account, the concentrations in CSF in patients with meningitis seem worth examining.
Cefuzoname (L-105) is a new, injectable cephalosporin developed by Lederle (Japan) Ltd. The compound has a wide antibacterial spectrum covering most aerobic and anaerobic gram-positive and gram-negative bacteria. The activity of cefuzoname is similar to that of cefazolin against staphylococci and to those of broad-spectrum cephems against gram-negative bacteria (M. Hikida, M. Inoue, and S. Mitsuhashi, Program Abstr. 24th Intersci. Conf. Antimicrob. Agents Chemother., abstr. no. 733, 1984) .
In view of the antibacterial potency of cefuzoname, it was thought that the compound might be effective in the therapy of purulent meningitis if it showed good penetration into Staphylococcal meningitis was induced by a method reported previously (11) . S. aureus FDA 209 P was cultured in brain heart infusion overnight, and a 5-ml portion of the culture was inoculated into 100 ml of brain heart infusion and then shake cultured for 3 h. The culture was centrifuged, and the resultant precipitates were washed three times by suspending them in physiological saline and centrifuging them. The final washed cells were resuspended in the physiological saline to an optical density of 0.7 at 550 nm. The viable cell count of this suspension was approximately 108/ml, and no decrease in the viable cell count was observed during a 3-month period while the suspension was stored at -20°C. A (6) cerebrospinal fluid (CSF); thus, the present study on its CSF penetration in rabbits was performed. in the CSF. However, meningitis was observed histologically. Rabbits with E. coli meningitis were deadly exhausted at 24 h after inoculation. If untreated, the animals would Z Z have died in about 48 h by an increase of E. coli in the CSF.
MATERIALS AND METHODS

Meningitis
Over a period of about 5 min, cefuzoname (100 mg/kg) was U oî nfused through the ear vein into 10 rabbits with staphylococcal meningitis, 10 rabbits with E. coli meningitis, and 10 healthy rabbits. In infected rabbits the infusion was performed 24 h after inoculation. Samples of blood and CSF were collected at 15 In many rabbits of the E. coli meningitis group the t1/2 in CSF was lengthy, showing a significant difference in mean values between this group and the staphylococcal meningitis group. However, no significant difference was observed with respect to the t1/2 between the E. coli meningitis group and the healthy group, which fact was thought to be attributable to a persistent low concentration in the CSF of one rabbit in the healthy group, the tj/2 of which was as long as 163 min.
DISCUSSION
The results of the study on cefuzoname in rabbits with staphylococcal meningitis were compared with those of other ,-lactam agents with 5-min intravenous infusion (Table  3) (2-9, 12-24, 26) . The Cmax and AUC CSF/serum of cefuzoname were similar to those of aztreonam, cefmenoxime, and cefpiramide and obviously superior to those of penicillin G, cefotiam, cefotetan, and cefsulodin, which places cefuzoname among the middle ranks of various ,-lactam agents as far as penetration is concerned.
Thus, it is probable that cefuzoname is effective on meningitis induced by bacteria against which the compound has an activity similar to that of penicillin G. Against both Streptococcus pneumoniae and Streptococcus pyogenes the MIC for 90% of the strains tested (MIC90) of cefuzoname is 0.012 ,ug/ml (Hikida et al., 24th ICAAC), whereas the MIC90 of penicillin G is less than 0.012 ,ug/ml against S. pneumoniae and 0.39 j,g/ml against Streptococcus agalactiae (1).
According to reports at the Pediatric Society conference in Japan, the concentrations of cefuzoname in CSF in pediatric patients with purulent meningitis are 3 to 6 jig/ml in many cases at the early stage of the disease (personal communication). It is also emphasized (25, 27, 28) that, even if the concentration in CSF reaches the in vitro MBC, the bactericidal potency is not sufficient in vivo. Opinions vary as to how many times the in vitro MBC is necessary for bactericidal activity in vivo; however, on the assumption that the bactericidal potency required for a living body is at least 10-fold the in vitro MBC, and taking the above-mentioned clinical reports on CSF concentrations into account, it is thought that cefuzoname can be used safely for meningitis caused by pathogens for which the MBC for 90% of strains tested (MBC90) of this compound is below 0.3 ,ug/ml. Be study on two strains isolated from patients with meningitis showed that the MICs of cefuzoname were 0.05 and 0.025 ,ug/ml, whereas the MBC was 0.05 ,ug/ml for both strains. The MIC of ampicillin was 0.1 ,ug/ml for both strains, and the MBCs were 0.1 and 0.2 pug/ml. Since S. agalactiae, E. coli, H. influenzae, and S. pneumoniae are the principal causative bacteria of pediatric purulent meningitis, and more than half of the total cases whose causative bacteria are identified involve these pathogens (10), the compound is considered to be usable for the therapy of meningitis, although further studies on the susceptibility of S. agalactiae to cefuzoname in a larger number of strains are required. The antibacterial activity of cefuzoname on Neisseria meningitidis has not yet been measured. In Japan, meningitis caused by this etiological agent is rarely encountered (10), but it has been considered necessary to study the effect of this compound on the meningitis which is common in other regions of the world. Although activity against staphylococci is claimed to be a strong point of cefuzoname, the MIC90 is 25 ,ug/ml against S. aureus and Staphylococcus epidermidis, and the percentage of inhibition of bacterial growth below 0.3 ,g/ml is 10% for S. aureus and 25% for S. epidermidis; thus, efficacy appears to be limited. Even so, this compound is still superior to other broad-spectrum cephems. Since the current therapeutic status is such that adequate antibiotics for staphylococcal meningitis are lacking, this antibiotic can be considered beneficial if it is safely usable for meningitis, even if the applicable cases are limited.
In sum, the results of the present study suggest that extensive clinical investigations on the penetration of cefuzoname into the CSF of patients with meningitis are worth conducting.
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